Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 5, Issue 5 (2016)

Exenatide use for the correction of morphological changes of pituitary-adrenal system in experimental diabetes mellitus

Author(s):
VA Levytskyi, OYa Zhurakivska, Yu L Tkachuk
Abstract:
The research work is devoted to issues of morpho-functional changes of pituitary-adrenal system in diabetes mellitus and its correction with exenatide and insulin. On the 28th day of streptozotocin-induced diabetes mellitus development we noticed the increase in number of corticotrophs of adenohypophysis and elevation of their functional activity (extension of nucleus area and increase of nucleocytoplasmic index, volume density of secretory granules due to their marginated form), leading to the increase of adrenocorticotropic hormone (ACTH) in blood. Qualitative and quantitative alterations of corticotrophs and hyperglycemia result in adrenal cortex restructuring, namely: thickening of fascicular and reticular zones of adrenal cortex, enlargement of the area of profile field of endocrinocytes and their nuclei, significant increase of volume density of lipid droplets in cells, increase of blood cortisol level. The use of exenatide in the treatment of morphological disorders of pituitary-adrenal system in streptozotocin-induced diabetes mellitus results in regeneration of quantitative cellular composition of adenohypophysis and adrenal cortex, ultrastructural composition and secretory activity of corticotrophs and endocrinocytes of adrenal cortex, decrease of adrenocorticotropic hormone and cortisol levels in blood, as well as normalization of glucose level and glycosylated hemoglobin.
Pages: 76-80  |  947 Views  10 Downloads
How to cite this article:
VA Levytskyi, OYa Zhurakivska, Yu L Tkachuk. Exenatide use for the correction of morphological changes of pituitary-adrenal system in experimental diabetes mellitus. Pharma Innovation 2016;5(5):76-80.
The Pharma Innovation Journal